<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>

Abstract

This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). Methods: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. Results: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2-5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. Conclusion: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients.

Conditional disease‐free survival rates and their associated determinants in patients with epithelial ovarian cancer: A 15‐year retrospective cohort study

“…A study conducted on EOC patients indicated that more than one parity improved OS in ASEOC patients 3 . However, the results of the current study did not show any relationship between the CDFS of EOC women and their parity.…”

“…The most common type of OC is epithelial ovarian cancer (EOC) which is the most lethal gynecologic malignancy in adult women 1 . The estimated overall 5‐year survival rate for early‐stage epithelial ovarian cancer patients (ESEOC: stages I and II) and patients with advanced‐stage epithelial ovarian cancer (ASEOC: stages III and IV) varies between 55% and 92% and 18% and 30%, respectively 2,3 …”

“…The statistical measures made at the time of diagnosis are traditionally used for evaluating the survival rate. In this regard, two types of traditionally used survival estimates in previous studies are overall survival (OS) and disease‐free survival (DFS) which are reported from the time of diagnosis and remission, respectively 3‐6 . Despite providing important information for both clinicians and patients, such analyses appear to be of less value for patients who survive a period of time after their initial diagnosis and treatment 7 .…”

“… 1 The estimated overall 5‐year survival rate for early‐stage epithelial ovarian cancer patients (ESEOC: stages I and II) and patients with advanced‐stage epithelial ovarian cancer (ASEOC: stages III and IV) varies between 55% and 92% and 18% and 30%, respectively. 2 , 3 …”

“…In this regard, two types of traditionally used survival estimates in previous studies are overall survival (OS) and disease‐free survival (DFS) which are reported from the time of diagnosis and remission, respectively. 3 , 4 , 5 , 6 Despite providing important information for both clinicians and patients, such analyses appear to be of less value for patients who survive a period of time after their initial diagnosis and treatment. 7 Although most patients with EOC attain remission, most of them eventually relapse.…”